Fetal Microchimeric Cells for Maternal Cardiovascular Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current interventions for heart disease in women are inadequate due to the complexity of sex-specific cardiovascular physiology, and there is a need for a mechanism to link fetal cell trafficking in pre-term birth to subsequent maternal heart disease risk.
Innovation Solution
A method involving the measurement of fetal microchimeric cells or extracellular vesicles in biological samples using machine learning algorithms to determine the risk of maternal cardiovascular disease, with specific markers indicating increased or decreased risk, and administration of anti-infective agents to treat infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If fetal microchimeric cells are used for regenerative medicine, then tissue repair and regeneration are improved, but the risk of autoimmune diseases and tumor formation increases
Solution Approach 1:
The patent applies local quality by directing fetal microchimeric cells to specific injured tissues through chemotactic signals and extracellular matrix interactions. The cells exhibit site-specific differentiation and integration only at the injury location, maintaining their regenerative function locally while avoiding systemic autoimmune responses in other tissues.
Solution Approach 2:
The patent uses extracellular vesicles and secreted factors as intermediaries between fetal microchimeric cells and host tissues. These mediators facilitate tissue repair and immunomodulation without requiring direct integration of fetal cells into host organs, thereby reducing the risk of autoimmune rejection and tumorigenesis while maintaining regenerative benefits.
2Reliability
If fetal microchimeric cells are introduced to treat maternal heart disease, then cardiac function is improved, but the complexity of sex-specific cardiovascular physiology makes treatment optimization difficult
Solution Approach 1:
The patent employs parameter changes by adjusting fetal cell dosage, timing of administration relative to pregnancy stages, and selective expansion of specific fetal cell subpopulations in vitro. These parameter optimizations account for sex-specific cardiovascular differences and pregnancy-related physiological changes, enabling tailored treatment protocols that improve cardiac function while simplifying clinical implementation.
3Strength
If fetal extracellular vesicles are used for regenerative therapy, then tissue repair is enhanced with reduced immune rejection, but the mechanism linking fetal cell trafficking in pre-term birth to maternal heart disease risk remains unclear
Solution Approach 1:
The patent applies preliminary action by using fetal extracellular vesicles to modulate maternal cardiovascular physiology during pregnancy before disease manifestation. The vesicles prepare the maternal cardiovascular system for future stressors and injuries, establishing a protective mechanism that reduces later disease risk while maintaining tissue repair capabilities.
Solution Approach 2:
The patent incorporates feedback mechanisms where fetal extracellular vesicles respond to maternal physiological signals and injury contexts, adjusting their cargo composition and release patterns. This feedback loop provides real-time information about maternal cardiovascular status, enabling dynamic adaptation of regenerative therapy while revealing mechanistic insights into fetal-maternal cellular communication.
Data Source
AI summary
Provided herein are methods and compositions for determining an increased risk of maternal cardiovascular disease caused by an infection comprising: obtaining, or having obtained, a biological sample from a subject at risk of, of having had a pre-term birth; measuring fetal microchimeric cells or fetal extracellular vesicles in the biological sample; and using a machine learning algorithm calculating a risk of cardiovascular disease based on the an increase or a decrease in fetal microchimeric cells in the biological sample when compared to a maternal sample from a subject that does not have an infection.